Compare Amylx Pharmaceuticals Inc (AMLX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Johnson Controls International PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Johnson Controls International PLC trades at $142.77 (market cap $87.13B). The key difference: Johnson Controls International PLC is far larger — about 44× Amylx Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.12% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | JCI | |
|---|---|---|
Market Cap | $1.98B | $87.13B |
Sector | Health | Industrials |
52-Week High | $18.70 | $148.21 |
52-Week Low | $7.64 | $103.24 |
Enterprise Value | $1.70B | $95.96B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Johnson Controls International (JCI) trades at $142.81, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a net income margin of 14.45% and a consensus analyst price target of $153.67. Recent news highlights expansion in data center cooling and smart home markets, supported by a dividend of $0.40 per share payable in July 2026.
JCI's outlook is supported by earnings momentum and strategic acquisitions, but risks include high valuation multiples and bearish technical indicators. The stock offers potential upside to analyst targets, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
